Circulating DNA: A new diagnostic gold mine?

Cancer Treatment Reviews

Volumn 28, Issue 5, 2002, Pages 255-271

  Ziegler, Annemarie ^a   Zangemeister Wittke, Uwe ^a   Stahel, Rolf A ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Cancer diagnosis; Disease management; Noninvasive approaches; Plasma DNA

Indexed keywords

DNA; MICROSATELLITE DNA; NUCLEIC ACID; TUMOR MARKER;

ACUTE GRANULOCYTIC LEUKEMIA; BLADDER CANCER; BLOOD SAMPLING; BREAST CANCER; CANCER DIAGNOSIS; CELL DEATH; CELL FREE SYSTEM; COLORECTAL CANCER; DIAGNOSTIC VALUE; DIGESTIVE SYSTEM CANCER; DISEASE COURSE; DISEASE MARKER; DNA DETERMINATION; EARLY DIAGNOSIS; GENE MUTATION; HEAD AND NECK CANCER; HUMAN; KIDNEY CANCER; LUNG CANCER; MELANOMA; MYELODYSPLASTIC SYNDROME; NASOPHARYNX CANCER; ONCOGENE; PANCREAS CANCER; PROGNOSIS; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0036815845     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(02)00077-4     Document Type: Article

References (101)

1. Mandel P, Métais P. Les acides nucléiques du plasma sanguin chez l'homme. CR Acad Sci Paris 1948; 142: 241-243.
2. Tan EM, Schur PH, Carr RI, et al. Deoxyribonucleic acid (DNA) and antibodies to DNA in the serum of patients with systemic lupus erythematosus. J Clin Invest 1966; 45: 1732-1740.
3. Leon SA, Shapiro B, Sklaroff DM, et al. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 1977; 37: 646-650.
4. Carpentier NA, Izui S, Rose LM, et al. The presence of circulating DNA in patients with acute or chronic leukemia: Relation to serum anti-DNA antibodies and Clq binding activity. Hum Lymphocyte Diff 1981; 1: 93-104.
5. Shapiro B, Chakrabarty M, Cohn EM, et al. Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease. Cancer 1983; 51: 2116-2120.
6. Stroun M, Anker P, Lyautey J, et al. Isolation and characterization of DNA from the plasma of cancer patients. Eur J Cancer Clin Oncol 1987; 23: 707-712.
7. Stroun M, Anker P, Maurice P, et al. Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology 1989; 46: 318-322.
8. Vasioukhin V, Anker P, Maurice P, et al. Point mutations of the N-ras gene in the blood plasma of patients with myelodysplastic syndrome or acute myelogenous leukemia. Br J Haematol 1994; 86: 774-779.
9. Sorenson GD, Pribish DM, Valone FH, et al. Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol Biomarkers Prev 1994; 3: 67-71.
10. Fournié GJ, Bret L, Belenguer P, et al. Physicochemical characterization of plasma DNA. Lupus 1992; 1: 186.
11. Savill J, Fadock V, Hensons P, et al. Phagocyte recognition of cells undergoing apoptosis. Immunol Today 1993; 14: 131-136.
12. Fournié GJ, Courtin J-P, Laval F, et al. Plasma DNA as a marker of cancerous cell death. Investigations in patients suffering from lung cancer and in nude mice bearing human tumours. Cancer Lett 1995; 91: 221-227.
13. Jahr S, Hentze H, English S, et al. DNA fragments in the blood plasma of cancer patients: Quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001; 61: 1659-1665.
14. Rogers JC, Boldt D, Kornfeld S, et al. Excretion of deoxyribonucleic acid by lymphocytes stimulated with phytohaemagglutinin or antigen. Proc Natl Acad Sci USA 1972; 69: 1685-1689.
15. Chen XQ, Bonnefoi H, Diebold-Berger, et al. Detecting tumour-related alterations in plasma or serum DNA of patients diagnosed with breast cancer. Clin Cancer Res 1999; 5: 2297-2303.
16. Lee T-H, Montalvo L, Chrebtow V, et al. Quantitation of genomic DNA in plasma and serum samples: higher concentrations of genomic DNA found in serum than in plasma. Transfusion 2001; 41: 276-282.
17. Lui YYN, Chik KW, Chiu RWK, et al. Predominant haematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation. Clin Chem 2002; 48: 421-427.
18. Lo YMD, Tein MSC, Lau TK, et al. Quantitative analysis of fetal DNA in maternal plasma and serum: Implications for noninvasive prenatal diagnosis. Am J Hum Genet 1998; 62: 768-775.
19. Chiu RWK, Poon LLM, Lau TK, et al. Effects of blood-processing protocols on fetal and total DNA quantification in maternal plasma. Clin Chem 2001; 47: 1607-1613.
20. De Kok JB, Hendriks JCM, van Solinge WW, et al. Use of real-time quantitative PCR to compare DNA isolation methods. Clin Chem 1998; 44: 2201-2204.
21. Gonzalez R, Silva JM, Sanchez A, et al. Microsatellite alterations and TP53 mutations in plasma DNA of small-cell lung cancer patients: follow-up study and prognostic significance. Ann Oncol 2000; 11: 1097-1104.
22. Kopreski MS, Benko FA, Borys DJ, et al. Somatic mutation screening: identification of individuals harboring K-ras mutations with the use of plasma DNA. J Natl Cancer Inst 2000; 92: 918-923.
23. Thijssen MA, Swinkels DW, Ruers TJ, et al. Difference between free circulating plasma and serum DNA in patients with colorectal liver metastasis. Anticancer Res 2002; 22: 421-425.
24. Shao Z-M, Wu J, Shen Z-Z, et al. p53 mutation in plasma DNA and its prognostic value in breast cancer patients. Clin Cancer Res 2001; 7: 2222-2227.
25. Sozzi G, Conte D, Mariani L, et al. Analysis of circulating tumour DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res 2001; 61: 4675-4678.
26. Paesmans M, Sculier JP, Libert P, et al. Prognostic factors for survival in advanced non-small cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1052 patients. J Clin Oncol 1995; 13: 1221-1230.
27. Castells A, Puig P, Móra J, et al. K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance. J Clin Oncol 1999; 17: 578-584.
28. Yamada T, Nakamori S, Ohzato H, et al. Detection of K-ras gene mutations in plasma of patients with pancreatic adenocarcinoma: correlation with clinicopathological features. Clin Cancer Res 1998; 4: 1527-1532.
29. Mulcahy HE, Lyautey J, Lederrey C, et al. A prospective study of K-ras mutations in the plasma of pancreatic cancer patients. Clin Cancer Res 1998; 4: 271-275.
30. Anker P, Lefort F, Vasioukhin V, et al. K-ras mutations are found in DNA extracted from the plasma of patients with colorectal cancer. Gastroenterology 1997; 112: 1114-1120.
31. Kopreski MS, Benko FA, Kwee C, et al. Detection of mutant K-ras DNA in plasma or serum of patients with colorectal cancer. Br J Cancer 1997; 76: 1293-1299.
32. Mulcahy HE, Lyautey J, Lederrey C, et al. Plasma DNA K-ras mutations in patients with gastrointestinal malignancies. Ann NY Acad Sci 2000; 906: 25-28.
33. Kirk GD, Camus-Randon A-M, Mendy M, et al. Ser-249 p53 mutations in plasma DNA of patients with hepatocellular carcinoma from the Gambia. J Natl Cancer Inst 2000; 92: 148-153.
34. Jackson PE, Qian G-S, Friesen MD, et al. Specific p53 mutations detected in plasma and tumours of hepatocellular carcinoma patients by electrospray ionization mass spectrometry. Cancer Res 2001; 61: 33-35.
35. Mayall F, Jacobson G, Wilkins R, et al. Mutations of p53 gene can be detected in the plasma of patients with large bowel carcinoma. J Clin Pathol 1998; 51: 611-613.
36. Silva JM, Garcia JM, Dominguez G, et al. Persistence of tumour DNA in plasma of breast cancer patients after mastectomy. Ann Surg Oncol 2002; 9: 71-76.
37. Silva JM, Dominguez G, Garcia JM, et al. Presence of tumour DNA in plasma of breast cancer patients: clinicopathological correlations. Cancer Res 1999; 59: 3251-3256.
38. Gocke CD, Benko FA, Kopreski MS, et al. p53 and APC mutations are detectable in the plasma and serum of patients with colorectal cancer (CRC) or adenomas. Ann NY Acad Sci 2000; 906: 44-50.
39. Hibi K, Robinson CR, Booker S, et al. Molecular detection of genetic alterations in the serum of colorectal cancer patients. Cancer Res 1998; 58: 1405-1407.
40. Dahse R, Utting M, Werner W, et al. TP53 alterations as a potential diagnostic marker in superficial bladder carcinoma and in patients serum, plasma, and urine samples. Int J Oncol 2002; 20: 107-115.
41. Coulet F, Blons H, Cabelguenne A, et al. Detection of plasma tumour DNA in head and neck squamous cell carcinoma by microsatellite typing and p53 mutation analysis. Cancer Res 2000; 60: 707-711.
42. Baylin S, Herman JG. DNA hypermethylation in tumourigenesis: epigenetics joins genetics. Trends Genet 2000; 16: 168-174.
43. Herman JG, Graft JR, Myhnen S, et al. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996; 93: 9821-9826.
44. Usadel H, Brabender J, Danenberg KD, et al. Quantitative adenomatous polyposis coli promoter methylation analysis in tumour tissue, serum, and plasma of patients with lung cancer. Cancer Res 2002; 62: 371-375.
45. Esteller M, Sanchez-Cespedes M, Rosell R, et al. Detection of aberrant promoter hypermethylation of tumour suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 1999; 59: 67-70.
46. INK4a gene in plasma DNA of breast cancer patients. Br J Cancer 1999; 80: 1262-1264.
47. Wong IHN, Johnson PJ, Lai PSB, et al. Tumour-derived epigenetic changes in the plasma and serum of liver cancer patients. Ann NY Acad Sci 2000; 906: 102-105.
48. Wong IHN, Lo YMD, Zhuang J, et al. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res 1999; 59: 71-73.
49. Hibi K, Taguchi M, Nakayama H, et al. Molecular detection of p16 promoter hypermethylation in the serum of patients with esophageal squamous cell carcinoma. Clin Cancer Res 2001; 7: 3135-3138.
50. Kawakami K, Brabender J, Lord RV, et al. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J Natl Cancer Inst 2000; 92: 1805-1881.
51. Grady WM, Rajput A, Lutterbaugh JD, et al. Detection of aberrantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer. Cancer Res 2001; 61: 900-902.
52. Wong TS, Chang HW, Tang KC, et al. High frequency of promoter hypermethylation of the death-associated protein-kinase gene in nasopharingeal carcinoma and its detection in the peripheral blood of patients. Clin Cancer Res 2002; 8: 433-437.
53. Dominguez G, Carballido J, Silva J, et al. p14ARF promoter hypermethylation in plasma DNA as an indicator of disease recurrence in bladder cancer patients. Clin Cancer Res 2002; 8: 980-985.
54. Wong IHN, Lo YMD, Johnson PJ. Epigenetic tumour markers in plasma and serum. Biology and applications to molecular diagnosis and disease monitoring. Ann NY Acad Sci 2001; 945: 36-50.
55. Mao L, Lee DJ, Tockman MS, et al. Microsatellite alterations as clonal markers for the detection of human cancer cells. Proc Natl Acad Sci USA 1994; 91: 9871-9875.
56. Bruhn N, Beinert T, Oehm C, et al. Detection of microsatellite alterations in the DNA isolated from tumour cells and from plasma DNA of patients with lung cancer. Ann NY Acad Sci 2000; 906: 72-82.
57. Sozzi G, Musso K, Ratcliffe C, et al. Detection of microsatellite alterations in plasma DNA of non-small cell lung cancer patients: a prospect for early diagnosis. Clin Cancer Res 1999; 5: 2689-2692.
58. Chen XQ, Stroun M, Magnenat J-L, et al. Microsatellite alterations in plasma DNA of small cell lung cancer patients. Nature Med 1996; 2: 1033-1034.
59. Allan JM, Hardie LJ, Briggs JA, et al. Genetic alterations in bronchial mucosa and plasma DNA from individuals at high risk of lung cancer. Int J Cancer 2001; 91: 359-365.
60. Shaw JA, Smith BM, Walsh T, et al. Microsatellite alterations in plasma DNA of primary breast cancer patients. Clin Cancer Res 2000; 6: 1119-1124.
61. Taback B, Fujiwara Y, Wang H-J, et al. Prognostic significance of circulating microsatellite markers in the plasma of melanoma patients. Cancer Res 2001; 61: 5723-5726.
62. Fujiwara Y, Chi DDJ, Wang HJ, et al. Plasma DNA microsatellites as tumour-specific markers and indicators of tumour progression in melanoma patients. Cancer Res 1999; 59: 1567-1571.
63. Utting M, Werner W, Dahse R, et al. Microsatellite analysis of free tumour DNA in urine, serum and plasma of patients: a minimally invasive method for the detection of bladder cancer. Clin Cancer Res 2002; 8: 35-40.
64. Von Knobloch R, Hegele A, Brandt H, et al. Serum DNA and urine DNA alterations of urinary transitional cell bladder carcinoma detected by fluorescent microsatellite analysis. Int J Cancer 2001; 94: 67-72.
65. Gonzalgo ML, Eisenberger CF, Lee SM, et al. Prognostic significance of preoperative molecular serum analysis in renal cancer. Clin Cancer Res 2002; 8: 1878-1881.
66. Eisenberger CF, Schoenberg M, Enger C, et al. Diagnosis of renal cancer by molecular analysis. J Natl Acad Inst 1999; 91: 2028-2032.
67. Von Knobloch R, Hegele A, Brandt H, et al. High frequency of serum DNA alterations in renal cell carcinoma detected by fluorescent microsatellite analysis. Int J Cancer 2002; 98: 889-894.
68. Goessl C, Heicappell R, Mnker R, et al. Microsatellite analysis of plasma DNA from patients with clear cell renal carcinoma. Cancer Res 1998; 58: 4728-4732.
69. Nunes DN, Kowalski LP, Simpson AJG. Circulating tumour-derived DNA may permit the early diagnosis of head and neck squamous cell carcinomas. Int J Cancer 2001; 92: 214-219.
70. Nawroz H, Koch W, Anker P, et al. Microsatellite alterations in serum DNA of head and neck cancer patients. Nature Med 1996; 2: 1035-1037.
71. Silva JM, Bonilla F. Correspondence Re: Coulet et al. Detection of plasma tumour DNA in head and neck squamous cell carcinoma by microsatellite typing and p53 mutation analysis. Cancer Res 2001; 61: 8595-8596.
72. Mao L. Microsatellite analysis. Applications and pitfalls. Ann NY Acad Sci 2000; 906: 55-62.
73. Kuroi K, Tanaka C, Toi M. Plasma nucleosome levels in node-negative breast cancer patients. Breast Cancer 1999; 6: 361-364.
74. Kuroi K, Tanaka C, Toi M. Clinical significance of plasma nucleosome levels in cancer patients. Int J Oncol 2001; 19: 143-148.
75. Holdenrieder S, Stieber P, Frg T, et al. Apoptosis in serum of patients with solid tumours. Anticancer Res 1999; 19: 2721-2724.
76. Holdenrieder S, Stieber P, Bodenmller H, et al. Nucleosomes in serum as a marker of cell death. Clin Chem Lab Med 2001; 39: 596-605.
77. Holdenrieder S, Stieber P, Bodenmller H, et al. Nucleosomes in serum of patients with benign and malignant diseases. Int J Cancer 2001; 95: 114-120.
78. Giacona MB, Ruben GC, Iczkowski KA, et al. Cell-free DNA in human blood plasma: Length measurements in patients with pancreatic cancer and healthy controls. Pancreas 1998; 17: 89-97.
79. Reddi KK, Holland JF. Elevated serum ribonuclease in patients with pancreatic cancer. Proc Natl Acad Sci USA 1976; 73: 2308-2310.
80. Komeda T, Fukuda Y, Sando T, et al. Sensitive detection of circulating hepatocellular carcinoma cells in peripheral venous blood. Cancer 1995; 75: 2214-2219.
81. Kopreski MS, Gocke CD. Cellular- versus extracellular-based assays. Comparing the utility in DNA and RNA molecular marker assessment. Ann NY Acad Sci 2000; 906: 124-128.
82. Kopreski MS, Benko FA, Kwak LW, et al. Detection of tumour messenger RNA in the serum of patients with malignant melanoma. Clin Cancer Res 1999; 5: 1961-1965.
83. Hasselmann DO, Rappl G, Rossler M, et al. Detection of tumour-associated mRNA in serum, plasma and blood cells from patients with disseminated malignant melanoma. Oncol Rep 2001; 8: 115-118.
84. Fleischhacker M, Beinert T, Ermitsch M, et al. Detection of amplifiable messenger RNA in the serum of patients with lung cancer. Ann NY Acad Sci 2001; 945: 179-188.
85. Silva JM, Rodriguez R, Garcia JM, et al. Detection of epithelial tumour RNA in the plasma of colon cancer patients is associated with advanced stages and circulating tumour cells. Gut 2002; 50: 530-534.
86. Chen XQ, Bonnefoi H, Pelte M-F, et al. Telomerase RNA as a detection marker in the serum of breast cancer patients. Clin Cancer Res 2000; 6: 3823-3826.
87. Kopreski MS, Floyd AB, Gocke CD. Circulating RNA as tumour marker. Detection of 5T4 mRNA in breast and lung cancer patients serum. Ann NY Acad Sci 2001; 945: 172-178.
88. Jernimo C, Nomoto S, Caballero OL, et al. Mitochondrial mutations in early stage prostate cancer and bodily fluids. Oncogene 2001; 20: 5195-5198.
89. Nomoto S, Yamashita K, Koshikawa K, et al. Mitochondrial D-loop mutations as clonal markers in multicentric hepatocellular carcinoma and plasma. Clin Cancer Res 2002; 8: 481-487.
90. Fliss MS, Usadel H, Caballero O, et al. Facile detection of mitochondrial DNA mutations in tumours and bodily fluids. Science 2000; 287: 2017-2019.
91. Shotelersuk K, Khorprasert C, Sakdikul S, et al. Epstein-Barr virus DNA in serum/plasma as a tumour marker for nasopharyngeal cancer. Clin Cancer Res 2000; 6: 1046-1051.
92. Lo YMD, Chan LYS, Chan ATC, et al. Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumour recurrence in nasopharyngeal carcinoma. Cancer Res 1999; 59: 5452-5455.
93. Lo YMD, Chan LYS, Lo K-W, et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 1999; 59: 118-1181.
94. Lei KIK, Chan LYS, Chan W-Y, et al. Diagnostic and prognostic implications of circulating cell-free Epstein-Barr virus DNA in natural killer/T-cell lymphoma. Clin Cancer Res 2002; 8: 29-34.
95. Lei KIK, Chan LYS, Chan WY, et al. Quantitative analysis of circulating cell-free Epstein-Barr virus (EBV) DNA levels in patients with EBV-associated lymphoid malignancies. Br J Haematol 2000; 111: 239-246.
96. Gallagher A, Armstrong AA, MacKenzie J, et al. Detection of Epstein-Barr virus (EBV) genomes in the serum of patients with EBV-associated Hodgkin's disease. Int J Cancer 1999; 84: 442-448.
97. Ngan RKC, Yip TTC, Cheng W-W, et al. Circulating Epstein-Barr virus DNA in serum of patients with lymphoepithelioma-like carcinoma of the lung: a potential surrogate marker for monitoring disease. Clin Cancer Res 2002; 8: 986-994.
98. Lo YMD, Chan WY, Ng EKW, et al. Circulating Epstein-Barr virus DNA in the serum of patients with gastric carcinoma. Clin Cancer Res 2001; 7: 1856-1859.
99. Dong SM, Pai SI, Rha S-H, et al. Detection and quantitation of human papillomavirus DNA in the plasma of patients with cervical carcinoma. Cancer Epidemiol Biomarkers Prev 2002; 11: 3-6.
100. Pornthanakasem W, Shotelersuk K, Termrungruanglert W, et al. Human papillomavirus DNA in plasma of patients with cervical cancer. BMC Cancer 2001; 1: 2.
101. Capone RB, Pai SI, Koch WM, et al. Detection and quantitation of human papillomavirus (HPV) DNA in the sera of patients with HPV-associated head and neck squamous cell carcinoma. Clin Cancer Res 2000; 6: 4171-4175.